The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
On January 31, the US Federal Trade Commission cleared the merger.
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Competition watchdog says 'high market concentration' in some segments a worry.
Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.
US country head, key departmental heads leave; more likely to follow.
The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.
The company sold over 21 crore (210 million) shares in Sun Pharma.
Sun maintained it would retain the best of both organisations to build a global pharma company.
FDA had also issued warning letters to Ranbaxy's Paonta Sahib and Dewas facilities as it found extensive problems and deviations from manufacturing norms.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States.
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
Recently, Ranbaxy and Wockhardt too were hauled up.
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.
Data also show that several other leading domestic pharma companies have recalled their products from the US
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Yusuf Hamied, Anji Reddy and Parvinder Singh are the real pioneers of the Indian pharmaceutical industry.
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Ranbaxy is understood to have pulled out of the race to acquire German pharmaceutical company Merck's generic business on concerns of over-valuation.
4 Ranbaxy facilities in India have been barred from exporting to US.
Launches cloud-based version of solution to target mid-size clients in life sciences.
The FDA has stepped up its efforts to ensure drug safety in recent months.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
Sun Pharma's Dilip Shanghvi is India's richest person.
Ties between India and the United States have been strained in recent years because of trade policies and patent disputes.
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
IT, pharma and FMCG stocks are the top performers in 2013.
As part of the charm offensive, New Delhi has invited global regulators -- including the FDA -- to visit Indian production units to get first-hand evidence of measures taken to ensure the quality of locally manufactured generics.
India on Monday raised serious concerns over the USFDA's audit inspections of Indian pharma companies and 'disproportionate penalties' in some instances and said it would submit a discussion document on the issues to the US.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Dilip Shanghvi has never tried to be everything to everybody.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances